Back to top

MorphoSys AG Unveils Cancer Drug Trial Progress

Morphosys (MOR) has released an update. MorphoSys AG is set to showcase new Phase 3 data on pelabresib for treating myelofibrosis at the ASCO Annua...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

MorphoSys AG Unsponsored ADR (MOR)